Axonics Modulation Technologies Inc Total Liabilities
Axonics Modulation Technologies Inc total liabilities. Based on the latest financial reports, Axonics Modulation Technologies Inc (AXNX) has total liabilities worth $109.68 Million USD as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can Axonics Modulation Technologies Inc fund operations to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Axonics Modulation Technologies Inc (2016–2023)
Total liabilities of Axonics Modulation Technologies Inc from 2016 to 2023. This chart illustrates how Axonics Modulation Technologies Inc's total liabilities have evolved over time, based on quarterly financial data. Check Axonics Modulation Technologies Inc (AXNX) asset resilience to evaluate the company's liquid asset resilience ratio.
Axonics Modulation Technologies Inc Competitors by Total Liabilities
The table below lists competitors of Axonics Modulation Technologies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Honmyue Enterprise Co Ltd
TW:1474
|
Taiwan | NT$1.54 Billion |
|
Tela Bio Inc
NASDAQ:TELA
|
USA | $75.60 Million |
|
JOSAPAR Joaquim Oliveira S.A. Participações
SA:JOPA3
|
Brazil | R$1.62 Billion |
|
Tevogen Bio Holdings Inc.
NASDAQ:TVGN
|
USA | $13.62 Million |
|
Triller Group Inc. Common Stock
NYSE:ILLR
|
USA | $363.62 Million |
|
American Tungsten & Antimony Ltd
AU:AT4
|
Australia | AU$825.31K |
|
Fiyta Holdings Ltd
SHE:200026
|
China | HK$351.90 Million |
|
Petershill Partners PLC
LSE:PHLL
|
UK | GBX1.42 Billion |
Liability Composition Analysis (2016–2023)
This chart breaks down Axonics Modulation Technologies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AXNX current and non-current assets.
Liquidity & Leverage Metrics
Axonics Modulation Technologies Inc Total Liabilities Ratios Explained
Axonics Modulation Technologies Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Axonics Modulation Technologies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Axonics Modulation Technologies Inc (2016–2023)
The table below shows the annual total liabilities of Axonics Modulation Technologies Inc from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $82.36 Million | -7.68% |
| 2022-12-31 | $89.21 Million | +36.19% |
| 2021-12-31 | $65.51 Million | +19.46% |
| 2020-12-31 | $54.84 Million | +48.93% |
| 2019-12-31 | $36.82 Million | +28.60% |
| 2018-12-31 | $28.63 Million | -55.79% |
| 2017-12-31 | $64.77 Million | +37.40% |
| 2016-12-31 | $47.14 Million | -- |
About Axonics Modulation Technologies Inc
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retent… Read more